Express Scripts Holding Co.  (ESRX)
Other Ticker:  

Express Scripts Holding Co's



ESRX Sales vs. its Competitors Q3 2018

Comparing the current results to its competitors, Express Scripts Holding Co reported Revenue increase in the 3 quarter 2018 by 3.56 % year on year.
The sales growth was above Express Scripts Holding Co's competitors' average revenue growth of 2.11 %, achieved in the same quarter.

List of ESRX Competitors

With a net margin of 4.2 % Express Scripts Holding Co achieved higher profitability than its competitors.

More on ESRX Profitability Comparisons

Revenue Growth Comparisons

Net Income Comparison

Express Scripts Holding Co.Net Income in the 3 quarter 2018 grew year on year by 27.08%, faster than the Express Scripts Holding Co's competitors average income growth of 11.48 %

<<  ESRX Stock Performance Comparisons

Express Scripts Holding Co's Comment on Competitors and Industry Peers

There are a number of other PBMs in the United States against which we compete. Some of these are independent PBMs, such as Catamaran and MedImpact. Others are owned by managed care organizations such as Aetna Inc., CIGNA Corporation, Humana, OptumRx (owned by UnitedHealth Group) and Prime Therapeutics (owned by a collection of Blue Cross Blue Shield Plans). Some are owned by retail pharmacies, such as CVS Caremark (owned by CVS).

Wal-Mart Stores, Inc. may continue to engage in certain activities competitive with PBMs. We also compete against adjudicators, such as Argus. With the emergence of alternative benefit models through Private Exchanges, the competitive landscape also includes brokers, health plans and consultants. Some of these competitors may have greater financial, marketing and technological resources.

In addition, other companies may enter into the business and become increasingly competitive as barriers to entry are relatively low. We believe the primary competitive factors in the industry include the ability to contract with retail pharmacies to ensure our retail pharmacy networks meet the needs of our clients and their members, the ability to negotiate discounts on prescription drugs with drug manufacturers, the ability to navigate the complexities of governmental reimbursed business, including Medicare Part D, Medicaid and the Public Exchanges, the ability to manage cost and quality of specialty drugs, the ability to utilize the information we obtain about drug utilization patterns and consumer behavior to reduce costs for our clients and members, and the level of service that we provide.